{"id":"W2797366988","doi":"10.1016/s1556-0864(18)30402-7","title":"128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Osimertinib; Medicine; Gefitinib; Internal medicine; Erlotinib; Oncology; Discontinuation; Hazard ratio; Erlotinib Hydrochloride; Lung cancer; T790M; Progression-free survival; Ceritinib; Cancer; Chemotherapy; Epidermal growth factor receptor; Crizotinib; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000684638,0.0002937448,0.0006902664,0.0002755722,0.0001979644,0.0008198966,0.0002934072,0.0005617204,0.003827352],"category_scores_gemma":[0.001068402,0.000109996,0.002373907,0.000350928,0.0002659979,0.0007897015,0.0004099645,0.001006462,0.0003829974],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008821444,"about_ca_system_score_gemma":0.0006767488,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002330541,"about_ca_topic_score_gemma":0.005944176,"domain_scores_codex":[0.9996418,0.00008112741,0.00002583955,0.00006202347,0.00004345528,0.0001456909],"domain_scores_gemma":[0.9995307,0.0001078828,0.0001515422,0.00002152971,0.00003150617,0.000156962],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.417358,0.004277606,0.3837251,0.0008717566,0.004397586,0.0005341045,0.0002406424,0.003468817,0.004276772,0.000866124,0.01032185,0.1696618],"study_design_scores_gemma":[0.02064215,0.1042397,0.8522031,0.000335491,0.005753212,0.0008453457,0.0006280725,0.004010451,0.002433045,0.001561956,0.007258738,0.00008874735],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994059,0.001442673,0.0000625238,0.0003202172,0.00009220338,0.00004547332,0.001329735,0.000008647671,0.002639654],"genre_scores_gemma":[0.9969174,0.0004024467,0.00005505919,0.0001730245,0.00008649356,0.00002696377,0.001461152,0.000002396176,0.0008751329],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003827352,"threshold_uncertainty_score":0.01280379,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01162484789020192,"score_gpt":0.4255072744811524,"score_spread":0.4138824265909505,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}